Atossa Therapeutics – Developing Innovative Therapies To Address Unmet Needs In Breast Cancer
Dr. Steven Quay, Chairman of the Board and CEO of Atossa Therapeutics, a company focused on preventing breast cancer in at-risk women and treating breast cancer in women of all ages, discusses the development of a drug called (z)-endoxifen for breast cancer treatment which is currently undergoing 3 separate phase 2 clinical trials in the US.
Steven Quay is the founder of Seattle-based Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions.
He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and was on the faculty of Stanford University School of Medicine. His contributions to medicine have been cited over 9,600 times.
He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 US patents. Over 80 million people have benefited from the medicines he invented.
His current passion is the prevention of the two million yearly breast cancer cases worldwide.
